Dercle Laurent, Connors Dana E, Tang Ying, Adam Stacey J, Gönen Mithat, Hilden Patrick, Karovic Sanja, Maitland Michael, Moskowitz Chaya S, Kelloff Gary, Zhao Binsheng, Oxnard Geoffrey R, Schwartz Lawrence H
Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00137.
To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors.
The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement.
The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point.
The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.
建立公私合作关系,研究一种新方法在收集和分析晚期实体瘤标志性 III 期试验中临床注释影像数据方面的可行性。
临床试验的收集满足以下纳入标准:完成的针对超过 300 名患者的随机试验、高度可测量的实体瘤(非小细胞肺癌、结直肠癌、肾细胞癌和黑色素瘤),且需要申办方和机构审查委员会批准。分析计算机断层扫描的新方法是将其转移至学术影像分析实验室,使用集成到开源影像平台 Weasis 中的内部开发算法半自动绘制轮廓,并进行系列体积测量。
与五个申办方签订合同的中位时长为 12 个月。收集了涉及 20 个试验组 12 种治疗方案的 7085 例患者的 10 项试验。截至目前,分析了 3954 例患者的 4 项试验。97%的试验患者(n = 3837)的源影像数据被转移至学术核心。从 82%的已转移计算机断层扫描(n = 3162)中提取了肿瘤影像测量值。提取失败的原因包括不可测量的疾病(n = 392)、单一影像时间点(n = 224)和二次采集的图像(n = 59)。总体而言,79%的患者(n = 3055)提取了临床注释影像数据,且每项试验的主要试验终点分析仍代表每个原始试验终点。
大型随机试验源影像数据的共享和分析是可行的,为未来关于新的试验水平反应和进展影像指标的研究提供了丰富且可重复使用但很大程度上未被利用的资源。